TeleMD, a Russian start-up, is developing a software platform that uses artificial intelligence (AI) for cancer diagnostics and prognostication.
Over the past few months the start-up has been focused on fine-tuning the platform’s image recognition functionality for cancer diagnostics, and also on making the solution scalable for medical specialists from across disciplines to be able to analyze heterogeneous medical data. Sergei Sorokin, the TeleMD project leader, expressed hope late last year that his platform would be marketed as “both a cloud-based solution and a self-contained software product.”
The TeleMD platform is designed to enable physicians to diagnose and predict oncologic developments in complicated cases by analyzing medical images and other patient-specific data. With the solution, doctors may expect to be able to reach out to broader medical communities and get remote advice. TeleMD is reported to have developed its diagnostics criteria and algorithms in close collaboration with experts from the Moscow-based Russian Blokhin Research Center for Oncology and some other leading scientific hubs and clinical centers.
Last September the start-up received more than $180,000 for the software platform from Primer Capital, a Russian VC fund focused on biotech.